NCT01846416 / 2013-000177-69: A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR] |
|
|
| Completed | 2 | 138 | US, Europe | Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody | Genentech, Inc. | Non-Small Cell Lung Cancer | 01/15 | 12/17 | | |
NCT02748889: Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer |
|
|
| Terminated | 1/2 | 1 | US | Carboplatin, Paraplatin, Etoposide, VP-16, Toposar, MPDL3280A, Atezolizumab | Giuseppe Giaccone, Vanderbilt University, Memorial Sloan Kettering Cancer Center | Small Cell Lung Cancer ( SCLC ) | 05/17 | 05/17 | | |